Clinical Trial

Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air at Rest

Study acronym: LOCONOZ3
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated April 27, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary purpose of this study is to measure pulmonary function, symptoms, and pulmonary inflammatory responses in healthy young adults during and immediately after exposure to a low concentration of ozone (0.070 ppm) or clean air for 6.6 hours while at rest. This concentration is the current EPA NAAQS standard for ozone.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-17.
Trial Details
NCT Number NCT06943989
Lead Sponsor Environmental Protection Agency (EPA)
Conditions Lung Inflammation, Experimental Lung Inflammation
Enrollment 40 participants
Start Date 2024-11-05
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-27